Version 1
: Received: 31 May 2023 / Approved: 2 June 2023 / Online: 2 June 2023 (03:58:07 CEST)
How to cite:
Borštnar, Š.; Arnol, M.; Večerić Haler, Ž.; Mlinšek, G. Preexposure Prophylaxis against COVID-19 with Tixagevimab/Cilgavimab in Slovenian National Cohort of Kidney Transplant Recipients. Preprints2023, 2023060122. https://doi.org/10.20944/preprints202306.0122.v1
Borštnar, Š.; Arnol, M.; Večerić Haler, Ž.; Mlinšek, G. Preexposure Prophylaxis against COVID-19 with Tixagevimab/Cilgavimab in Slovenian National Cohort of Kidney Transplant Recipients. Preprints 2023, 2023060122. https://doi.org/10.20944/preprints202306.0122.v1
Borštnar, Š.; Arnol, M.; Večerić Haler, Ž.; Mlinšek, G. Preexposure Prophylaxis against COVID-19 with Tixagevimab/Cilgavimab in Slovenian National Cohort of Kidney Transplant Recipients. Preprints2023, 2023060122. https://doi.org/10.20944/preprints202306.0122.v1
APA Style
Borštnar, Š., Arnol, M., Večerić Haler, Ž., & Mlinšek, G. (2023). Preexposure Prophylaxis against COVID-19 with Tixagevimab/Cilgavimab in Slovenian National Cohort of Kidney Transplant Recipients. Preprints. https://doi.org/10.20944/preprints202306.0122.v1
Chicago/Turabian Style
Borštnar, Š., Željka Večerić Haler and Gregor Mlinšek. 2023 "Preexposure Prophylaxis against COVID-19 with Tixagevimab/Cilgavimab in Slovenian National Cohort of Kidney Transplant Recipients" Preprints. https://doi.org/10.20944/preprints202306.0122.v1
Abstract
Tixagevimab/cilgavimab (TIXA/CILGA) was introduced in early 2022 as a promising new drug for pre-exposure prophylaxis against COVID-19 in immunocompromised patients. The aim of our study was to evaluate the efficacy and safety of TIXA/CILGA in a Slovenian national cohort of kidney transplant recipients as pre-exposure prophylaxis in the Omicron era. Demographic, clinical, laboratory, and therapeutic data were collected from electronic and paper medical rec-ords. Of the 106 patients who received TIXA/CILGA, 6 patients (5.7%) subsequently acquired SARS-CoV-2 breakthrough infection. The incidence of SARS-CoV-2 infection was only slightly lower compared with patients who did not receive TIXA/CILGA (7.0%). All patients who re-ceived TIXA/CILGA had a mild disease course, whereas 20% of patients who did not receive TIXA/CILGA required hospitalization and two patients died. Adverse effects most likely related to TIXA/CILGA occurred in 12% of patients, one of whom experienced deep vein thrombosis. None of the patients suffered acute myocardial infarction or cerebrovascular insult. Overall, the benefit of added protection for kidney transplant patients appears to outweigh the potential risk of adverse events and provide additional protection against severe COVID-19 protection.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
